IL-6 (Interleukin-6): The "Versatile Core Coordinator" of Immunity and Inflammation

IL-6 (interleukin-6) is one of the most versatile and widely influential core members of the cytokine network. It serves not only as a primary inducer of the acute-phase response but also as a critical messenger connecting innate and adaptive immunity, while regulating hematopoietic, metabolic, and neuroendocrine systems. Unlike cytokines with relatively specialized functions, IL-6 exhibits highly context-dependent and dualistic biological effects: it is essential for initiating protective defense and repair during acute infections or tissue damage, yet its excessive or sustained production drives core pathological mechanisms in chronic inflammation, autoimmune diseases, cytokine storms, and cancer cachexia. Thus, IL-6 is regarded as a pivotal "pleiotropic core coordinator" in immune and inflammatory responses.

I. Overview: Sources, Structure, and the Complex Receptor System

IL-6 can be rapidly produced by nearly all stromal and immune cells in response to stimuli, including macrophages, dendritic cells, T cells, B cells, fibroblasts, and endothelial cells. It is a glycoprotein with a molecular weight of approximately 21-26 kDa.

The functional complexity of IL-6 stems from its unique dual-receptor activation signaling system, a core feature distinguishing it from other cytokines:

Membrane-bound IL-6 receptor (classical signaling pathway):

IL-6Rα chain (CD126): This is the specific binding chain for IL-6, primarily expressed on hepatocytes, neutrophils, monocytes/macrophages, and certain lymphocytes. IL-6 first binds to membrane-bound IL-6Rα.

gp130 signal-transducing chain (CD130): A shared signaling transducer for IL-6, IL-11, and other cytokines. The IL-6/IL-6Rα complex then recruits and dimerizes gp130, initiating downstream signaling.

Physiological functions: This pathway primarily mediates IL-6's protective and regenerative roles, such as acute-phase protein synthesis in the liver, neutrophil mobilization, tissue repair, and certain anti-inflammatory responses.

Soluble IL-6 receptor and trans-signaling pathway (pathological signaling pathway):

Soluble IL-6R (sIL-6R): Generated through proteolytic shedding of membrane-bound IL-6R or alternative splicing. sIL-6R can bind IL-6 in bodily fluids.

Trans-signaling: The IL-6/sIL-6R complex can bind and activate any cell expressing gp130 (virtually all cells express gp130), vastly expanding IL-6's target cell repertoire.

Pathological functions: This pathway is considered the primary mechanism driving chronic inflammation, autoimmune diseases, and tumor progression. It enables IL-6 to act on cells that normally lack IL-6Rα, such as endothelial cells, synovial cells, neurons, and many tumor cells, triggering widespread pro-inflammatory and tissue-destructive effects.

II. Core Mechanisms: Dual Signaling Networks of Protection and Destruction

Through the two aforementioned signaling pathways, IL-6 initiates截然不同的生物学程序。

1. Classical signaling pathway: Coordinating systemic defense and repair

Induction of acute-phase response: Acts on hepatocytes to strongly induce the synthesis of acute-phase proteins such as C-reactive protein and serum amyloid A, initiating a systemic defensive state.

Promotion of hematopoiesis and immune cell differentiation: Synergizes with other factors to promote hematopoietic stem cell differentiation and influences the differentiation of Th17 cells, follicular helper T cells, and plasma cells.

Metabolic and anti-inflammatory regulation: Participates in glucose and lipid metabolism regulation and, under specific conditions, induces anti-inflammatory factors like IL-10.

2. Trans-signaling pathway: Driving chronic inflammation and tissue damage

Endothelial cell activation: Increases vascular permeability and upregulates adhesion molecule expression, promoting leukocyte extravasation.

Osteoclastogenesis: Synergizes with RANKL to promote osteoclast differentiation, leading to bone erosion in diseases like rheumatoid arthritis.

Cell proliferation and anti-apoptosis: In many tumor cells, sustained trans-signaling activation promotes proliferation, survival, invasion, and metastasis.

3. Core signal transduction: The JAK-STAT3 pathway

Upon binding to the receptor complex, IL-6 primarily activates JAK1/JAK2/Tyk2 kinases coupled to gp130.

Activated JAKs phosphorylate gp130, recruiting and phosphorylating STAT3. Phosphorylated STAT3 forms dimers that translocate to the nucleus, regulating the expression of numerous genes related to proliferation, survival, inflammation, and metabolism. Persistent STAT3 activation is the central hub for IL-6-mediated chronic inflammation and tumor-promoting effects.

Additionally, auxiliary pathways such as MAPK and PI3K-Akt are also activated.

III. Downstream Applications: From Physiological Regulation to a Broad Disease Spectrum

Dysregulation of IL-6 signaling is closely linked to an astonishingly diverse spectrum of human diseases.

1. Autoimmune and inflammatory diseases

Rheumatoid arthritis: Synovial fluid contains extremely high levels of IL-6, which drives synovial hyperplasia, inflammatory cell infiltration, osteoclast activation, and systemic symptoms (fatigue, anemia) via trans-signaling. The success of tocilizumab (an anti-IL-6R monoclonal antibody) directly demonstrates IL-6's central pathogenic role in this disease.

Systemic juvenile idiopathic arthritis: IL-6 is the key cytokine mediating characteristic systemic symptoms such as remittent fever and rash.

Castleman disease: Particularly the idiopathic multicentric type, where symptoms are driven by excessive IL-6 production. Anti-IL-6 therapy is the standard treatment.

Giant cell arteritis and polymyalgia rheumatica: IL-6 participates in vasculitis pathology, and its serum levels serve as sensitive markers of disease activity.

2. Cytokine release syndrome (CRS)

CRS in CAR-T therapy and severe COVID-19: During intense immune activation (e.g., CAR-T therapy, severe COVID-19), massive immune cell production of IL-6 and other cytokines triggers a "cytokine storm." IL-6 is the core mediator of CRS pathophysiology, directly causing high fever, hypotension, capillary leakage, and multi-organ failure. Tocilizumab has become a first-line treatment for CRS.

3. Cancer

Tumor promotion and cachexia: Many tumor cells exploit autocrine or paracrine IL-6 loops to promote growth, metastasis, and drug resistance. IL-6 also contributes to cancer cachexia (wasting, anorexia) by affecting liver metabolism and the central nervous system.

Tumor immune microenvironment: IL-6 can enhance the function of myeloid-derived suppressor cells, suppress anti-tumor immunity, and potentially influence the efficacy of immune checkpoint inhibitors.

4. Other diseases

Depression and "sickness behavior": IL-6 can cross the blood-brain barrier or transmit signals via the vagus nerve to act on the central nervous system, inducing fatigue, anhedonia, social withdrawal, and other "sickness behaviors," linking inflammation to depression.

Atherosclerosis and metabolic syndrome: As a pro-inflammatory factor, IL-6 contributes to vascular endothelial dysfunction and insulin resistance.

IV. Future Prospects: From Targeted Blockade to Precision Modulation

Deeper understanding of IL-6's biological duality is driving the development of more precise intervention strategies.

Differentiating targeting of classical vs. trans-signaling pathways:

Developing drugs that selectively inhibit trans-signaling while preserving classical pathway functions (e.g., selective anti-sIL-6R antibodies, sgp130Fc proteins) aims to suppress pathological inflammation while retaining IL-6's beneficial roles in tissue repair and host defense, potentially improving treatment safety.

Novel inhibitors and combination therapy strategies:

JAK inhibitors: As key nodes blocking IL-6 downstream signaling, JAK inhibitors (e.g., tofacitinib, baricitinib) are widely used in RA and other diseases. Future research will explore their applications in more IL-6-related diseases and combinations with IL-6R blockers.

Combination with immune checkpoint inhibitors: In cancer therapy, exploring combinations of anti-IL-6/IL-6R drugs with PD-1/PD-L1 inhibitors aims to reverse IL-6-mediated immunosuppressive microenvironments and improve efficacy.

As a critical biomarker:

Serum IL-6 levels have become important biomarkers for assessing CRS severity, prognosis in infectious diseases like COVID-19, and disease activity in autoimmune disorders like RA. Future applications may enable more precise patient stratification and treatment guidance.

Immunomodulation for neuropsychiatric disorders:

Based on IL-6's role in depression and cognitive impairment, exploring anti-IL-6 therapies for refractory depression or neurodegenerative diseases associated with chronic inflammation.

Engineered IL-6 variants:

Developing tissue-targeted or receptor-biased IL-6 variants or fusion proteins to harness IL-6's regenerative functions (e.g., promoting liver regeneration, muscle repair) for regenerative medicine while avoiding systemic inflammatory side effects.

Summary

IL-6 is a powerful and highly complex "pleiotropic core coordinator" in the cytokine world. Through its classical and trans-signaling pathways, it plays dual roles as both angel and devil in health and disease: an essential messenger for host defense and tissue repair, yet a key driver of chronic inflammation, autoimmunity, and cancer progression. From the revolutionary success of tocilizumab in rheumatology and CRS treatment to its role as a molecular bridge linking "body" and "mind" in understanding depression, IL-6 research has profoundly transformed our knowledge of the immune-neuro-endocrine network. Moving forward, by more precisely distinguishing and targeting its beneficial and harmful pathways, we may harness this potent cytokine to achieve breakthroughs in treating refractory inflammatory, autoimmune, and cancerous diseases—ultimately directing its power toward protecting and restoring life.